Top Markets
Coin of the day
Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087
株式のランク #3185
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
株価
$10.35
時価総額
$6.19B
変化(1日)
3.79%
変化(1年)
4.34%
CN
取引 Gan & Lee Pharmaceuticals. (603087)

カテゴリー

Gan & Lee Pharmaceuticals.(603087)の収益
Aug 2026 時点の収益 TTM: 0
Gan & Lee Pharmaceuticals. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Gan & Lee Pharmaceuticals. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$11.03B -
US
$34.74B -
FR
- -
JP
$20.84B -
US
- -
CH